Safety of talimogene laherparepvec: a real‐world retrospective pharmacovigilance study based on FDA Adverse Event Reporting System (FAERS)
2024

Safety of Talimogene Laherparepvec: A Real-World Study

Sample size: 1138 publication Evidence: moderate

Author Information

Author(s): Hong Yifan, Cheng Kebin, Qu Han, Wang Yuting, Wang Yuanyuan, Fan Guorong, Wu Zhenghua

Primary Institution: Shanghai Jiao Tong University

Hypothesis

What are the risks of adverse events related to Talimogene Laherparepvec (T-VEC)?

Conclusion

The study found that while most adverse events associated with T-VEC were previously documented, four unexpected adverse events (sepsis, encephalitis, syncope, and lymphadenopathy) were also identified.

Supporting Evidence

  • 1138 individual case safety reports were analyzed.
  • Seven system organ classes showed statistically significant signals.
  • Unexpected adverse events included sepsis, encephalitis, syncope, and lymphadenopathy.

Takeaway

This study looked at the safety of a cancer treatment called T-VEC and found some side effects that doctors should be aware of.

Methodology

The study analyzed individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database from 2004 to 2023 using disproportionality analysis.

Potential Biases

Potential reporting bias due to the predominance of reports from the USA.

Limitations

The study is limited by the quality of reporting in the FAERS database and the inability to control for confounding variables.

Participant Demographics

The majority of reports were from the USA, with a near-equal distribution of male and female patients, and 34.4% of patients were aged 60 or older.

Statistical Information

Confidence Interval

95% CI for ROR and IC provided in the results.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/s40780-024-00388-0

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication